Abstract:Background Progressive fibrosing interstitial lung disease (ILD) is characterised by parenchymal scar formation, leading to high morbidity and mortality. The ability to predict this phenotype remains elusive. We conducted a proteomic analysis to identify novel plasma biomarkers of progressive fibrosing ILD and developed a proteomic signature to predict this phenotype. Methods Relative plasma concentrations for 368 biomarkers were determined with use of a semi-quantitative, targeted proteomic platform in patients with connective tissue disease-associated ILD, chronic hypersensitivity pneumonitis, or unclassifiable ILD who provided research blood draws at the University of California (discovery cohort) and the University of Texas (validation cohort). Univariable logistic regression was used to identify individual biomarkers associated with 1-year ILD progression, defined as death, lung transplant, or 10% or greater relative forced vital capacity (FVC) decline. A proteomic signature of progressive fibrosing ILD was then derived with use of machine learning in the University of California cohort and validated in the University of Texas cohort. Findings The discovery cohort comprised 385 patients (mean age 63.6 years, 59% female) and the validation cohort comprised 204 patients (mean age 60.7 years, 61% female). 31 biomarkers were associated with progressive fibrosing ILD in the discovery cohort, with 17 maintaining an association in the validation cohort. Validated biomarkers showed a consistent association with progressive fibrosing ILD irrespective of ILD clinical diagnosis. A proteomic signature comprising 12 biomarkers was derived by machine learning and validated in the University of Texas cohort, in which it had a sensitivity of 0.90 and corresponding negative predictive value of 0.91, suggesting that approximately 10% of patients with a low-risk proteomic signature would experience ILD progression in the year after blood draw. Those with a low-risk proteomic signature experienced an FVC change of +85.7 mL (95% CI 6.9 to 164.4) and those with a high-risk signature experienced an FVC change of -227.1 mL (-286.7 to -167.5). A theoretical clinical trial restricted to patients with a high-risk proteomic signature would require 80% fewer patients than one designed without regard to proteomic signature. Interpretation 17 plasma biomarkers of progressive fibrosing ILD were identified and showed consistent associations across ILD subtypes. A proteomic signature of progressive fibrosing ILD could enrich clinical trial cohorts and avoid the need for antecedent progression when defining progressive fibrosing ILD for clinical trial enrolment. Copyright (C) 2022 Elsevier Ltd. All rights reserved.

U-net Convolutional Neural Network applied to progressive fibrotic interstitial lung disease: is progression at CT scan associated with a clinical outcome?

Admission chest CT scan of intensive care patients with interstitial lung disease: Unveiling its limited predictive value through visual and automated analyses in a retrospective study (ILDICTO)

U-Net-based computed tomography quantification of viral pneumonia can predict fibrotic interstitial lung abnormalities at 3-month follow-up

Deep-learning CT imaging algorithm to detect usual interstitial pneumonia pattern in patients with systemic sclerosis-associated interstitial lung disease: association with disease progression and survival

Prognostic value of automated assessment of interstitial lung disease on CT in systemic sclerosis

Deep Learning-based Segmentation of CT Scans Predicts Disease Progression and Mortality in IPF

Fibrosis-Net: A Tailored Deep Convolutional Neural Network Design for Prediction of Pulmonary Fibrosis Progression From Chest CT Images

Interstitial lung disease diagnosis and prognosis using an AI system integrating longitudinal data

Severity-stratification of interstitial lung disease by deep learning enabled assessment and quantification of lesion indicators from HRCT images

Prediction of lung malignancy progression and survival with machine learning based on pre-treatment FDG-PET/CT

Prediction of Disease Progression in Patients with COVID-19 by Artificial Intelligence Assisted Lesion Quantification

Proteomic Biomarkers of Progressive Fibrosing Interstitial Lung Disease: a Multicentre Cohort Analysis.

A deep convolutional neural network architecture for interstitial lung disease pattern classification

Predicting progressive phenotype in patients with fibrotic interstitial lung disease

Improving prognostic accuracy in lung transplantation using unique features of isolated human lung radiographs

Interstitial lung disease: performance of neutrophil-lymphocyte ratio in predicting progression

Elastic Registration-driven Deep Learning for Longitudinal Assessment of Systemic Sclerosis Interstitial Lung Disease at CT.

Quantitative CT texture-based method to predict diagnosis and prognosis of fibrosing interstitial lung disease patterns

Towards the adoption of quantitative computed tomography in the management of interstitial lung disease

Prognostic effects of clinical and CT imaging features on critically ill patients with interstitial lung disease hospitalized in respiratory intensive care unit

Deep Learning-Based CT Imaging in the Diagnosis of Treatment Effect of Pulmonary Nodules and Radiofrequency Ablation